Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

uture experience and results to differ materially from those discussed in these forward-looking statements. Important factors that might cause such a difference include, but are not limited to, costs related to the Merger, failure of AVANT's stockholders to approve the Merger; AVANT's or Celldex's inability to satisfy the conditions of the Merger; AVANT's inability to maintain its NASDAQ listing; the risk that AVANT's and Celldex's businesses will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for new products and technologies; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that the combined company may be unable to successfully secure regulatory approval of and market its drug candidates; the risks associated with reliance on outside financing to meet capital requirements; risks associated with Celldex's new and uncertain technology; risks of the development of competing technologies; risks related to the combined company's ability to protect its proprietary technologies; risks related to patent-infringement claims; risks of new, changing and competitive technologies and regulations in the U.S. and internationally; and other events and factors disclosed previously and from time to time in AVANT's filings with the Securities and Exchange Commission, including AVANT's Annual Report on Form 10-K for the year ended December 31, 2006. The companies do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

This communication may be deemed to be solicitation material in respect of the proposed merger of AVANT and Celldex. In connection with the proposed merger, AVANT and C
'/>"/>

SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 With increasing clinical applications, the ... rise in active partnerships. The primary reason for ... quantitate CD4 cell markers in human immunodeficiency virus ... New analysis from Frost ... Market ( http://www.frost.com/nf0e ), finds the market earned ...
(Date:8/31/2015)... The Wolf Administration today announced 289 drug ... State Police and local police departments have ... Heroin and opioid overdose are the leading cause of ... more individuals than those involved in fatal motor vehicle ... drug overdose. " Pennsylvania ...
(Date:8/31/2015)... 31, 2015  The departments of Drug and Alcohol ... Gaudenzia Concept 90 to raise awareness for International Overdose ... Pennsylvania and help more Pennsylvanians ... recovery through the Building Bridges to Recovery ... every day to a disease that is fully treatable, ...
Breaking Medicine Technology:Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 2Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 3Clinical Applications of Flow Cytometry Instrumentation and Reagents are Transforming this Market with a High-Growth Path 4Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2
... Although 2010 brought healthcare reform, investors are wondering ... likely expect some volatility in the sector, as the ... either through a repeal effort or withholding funding for ... & Poor,s Equity Research. "Healthcare reform ...
... BOTHELL, Wash., Jan. 13, 2011 SCOLR Pharma, Inc. (OTCQB: ... begin trading in the over-the counter (OTC) market beginning January ... is expected to be quoted on the OTC Bulletin Board ... cease trading on the NYSE Amex Exchange at the close ...
Cached Medicine Technology:S&P Equity Research Issues Health Care Sector Predictions for 2011 2S&P Equity Research Issues Health Care Sector Predictions for 2011 3S&P Equity Research Issues Health Care Sector Predictions for 2011 4S&P Equity Research Issues Health Care Sector Predictions for 2011 5S&P Equity Research Issues Health Care Sector Predictions for 2011 6SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011 2
(Date:9/1/2015)... Francisco, Calif. (PRWEB) , ... September 01, 2015 ... ... to corporations, law firms and government entities, announced today that it has hired ... Senior Discovery Consultant. In this capacity, Sanderson will be responsible for establishing ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a locally-owned independent natural ... women for 19 years and found that, among those who had a stroke, people ... report is part of the September 2015 issue of “Natural Insights for Well Being,” ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... Brent Nelson, D.O., has joined its medical management team as an Associate Medical ... of all sizes and types in the U.S. and abroad. , Dr. ...
(Date:9/1/2015)... ... September 01, 2015 , ... Two of Washington D.C.’s most ... through food and dining. , Recently named “the next big thing” in the ... known for telling the whole story behind food and reclaiming culinary traditions on the ...
(Date:9/1/2015)... ... 01, 2015 , ... SC&H Group, a leading audit, tax, and consulting firm, ... of the Best” firm in the U.S., as well as being ranked a Top ... in the U.S., selected exclusively on performance in specific areas of financial and operational ...
Breaking Medicine News(10 mins):Health News:Former NFL Standout Scott Sanderson Joins eDiscovery Leader Discovia 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 2Health News:Dr. Brent Nelson Joins WorkCare, Inc., as Associate Medical Director 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... infection with a reduced susceptibility to the potent antibiotic drug ... Ford Hospital study. Researchers found that patients who contracted ... hospital longer, were more likely to have the infection return ... from it after 90 days than patients who do not ...
... (Toronto) Mental illness is associated with more lost work ... $51 billion annually in lost productivity. In the first study ... Mental Health (CAMH) have calculated the actual cost of mental ... cost of a leave for a physical illness. ...
... A drug developed at the University of Kansas has ... often leads to pain in the extremities and even amputations, ... article showing that KU-32 can stop and even reverse diabetic ... death of nerves in the extremities of individuals with diabetes. ...
... Karen Pallarito HealthDay Reporter , THURSDAY, Sept. ... through large, employer-sponsored health plans will see a number ... paying more for that coverage, employers and benefits consultants ... and higher contributions from the individual members of the ...
... health decision-makers need to collaborate in a more efficient ... of supply shortages for pediatric vaccines but also to ... coverage, according to research published by a University of ... Sheldon H. Jacobson, a professor of computer science ...
... issue of the Hastings Center Report ... state to legalize physician-assistance in dying, either do not ... such assistance. Both legal and moral reasons are identified. ... important for assuring that physician-assisted death is carried out ...
Cached Medicine News:Health News:Henry Ford Hospital study: hVISA linked to high mortality 2Health News:Mental health leaves most costly disability to Canadian employers 2Health News:Drug holds promise to halt debilitating condition of diabetes 2Health News:Drug holds promise to halt debilitating condition of diabetes 3Health News:Health Care Reform: Employees Face Greater Cost-Sharing 2Health News:Health Care Reform: Employees Face Greater Cost-Sharing 3Health News:Health Care Reform: Employees Face Greater Cost-Sharing 4Health News:Pediatric vaccine stockpile policies need to be revisited, researcher says 2Health News:Pediatric vaccine stockpile policies need to be revisited, researcher says 3Health News:Study finds most Oregon hospices do not fully participate in the Death with Dignity Act 2
The CH 2000 Cardiac Diagnostic system is a fully featured stress testing system that can include Microvolt T-Wave Alternans (MTWA) testing capability as an add-on feature. , ,Interfaces with Tra...
... The Volk G-1 trabeculum provides the highest ... Perfect for viewing and treating the trabecular meshwork. ... of the anterior chamber angle while the central ... view the posterior pole for signs of glaucoma ...
... AFX (Air Fluid eXchange) Lens ... designed for use in an ... its use as a primary ... low profile and sutureless design ...
... The 45° Prism is ... pathologies and are recommended ... (PDR, BRVO etc.) and ... can be used for ...
Medicine Products: